The long-term objective of this research is the development of statistical tools to improve scientific inference in cancer research, with a principal focus on the elucidation of the long-term effects of prevention and treatment interventions for breast cancer. A primary objective is to provide flexible semiparametric models to estimate and predict the population impact of prevention and adjuvant therapy on breast cancer using data from cancer screening trials and large prevalent cohort studies. Research will include a focus on methods that adjust for different biases encountered in such studies. A continuing effort is to provide a quantitative framework to determine optimal cancer screening schedules by balancing benefit and cost.
The specific aims of this competing renewal include: (1) to develop and evaluate a class of semiparametric density ratio models to test a treatment effect in right-censored length-biased data;(2) to develop a unified estimation and prediction tool for semiparametric transformation models applied to right- censored length-biased data;(3) to develop robust and efficient estimation and prediction procedures for semiparametric accelerated failure time models on right-censored length-biased data;(4) to develop estimation and prediction methods for data of uncertain time of disease initiation with or without a cure probability;(5) to optimize screening programs using decision theoretic approaches by explicitly incorporating different risk profiles and natural history distributions into the general model structure;and (6) to develop user-friendly computer codes linked to existing software for the medical and statistical communities.
New statistical models and methods are proposed to study some longstanding problems as well as newly emerging issues for data observed in cancer research, which are subject to biased sampling. With the proposed analytic methods, the improved estimations of screening benefit and treatment intervention will better inform health policy and clinical practice in breast cancer prevention and treatment.
|Lin, Heather Y; Bedrosian, Isabelle; Babiera, Gildy V et al. (2017) Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer 123:2618-2625|
|Liu, Hao; Shen, Yu; Ning, Jing et al. (2017) Sample size calculations for prevalent cohort designs. Stat Methods Med Res 26:280-291|
|Fujii, T; Kogawa, T; Dong, W et al. (2017) Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 28:2420-2428|
|Shen, Yu; Ning, Jing; Qin, Jing (2017) Nonparametric and semiparametric regression estimation for length-biased survival data. Lifetime Data Anal 23:3-24|
|Shaitelman, Simona F; Lin, Heather Y; Smith, Benjamin D et al. (2016) Practical Implications of the Publication of Consensus Guidelines by the American Society for Radiation Oncology: Accelerated Partial Breast Irradiation and the National Cancer Data Base. Int J Radiat Oncol Biol Phys 94:338-48|
|Ning, J; Peng, S; Ueno, N et al. (2015) Has racial difference in cause-specific death improved in older patients with late-stage breast cancer? Ann Oncol 26:2161-8|
|Fouad, Tamer M; Kogawa, Takahiro; Liu, Diane D et al. (2015) Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152:407-16|
|Fujii, Takeo; Le Du, Fanny; Xiao, Lianchun et al. (2015) Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol 1:1311-8|
|Middleton, Lavinia P; Sneige, Nour; Coyne, Robin et al. (2014) Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Med 3:492-9|
|Shih, Ya-Chen Tina; Xu, Ying; Dong, Wenli et al. (2014) First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer. Breast Cancer Res Treat 144:417-25|
Showing the most recent 10 out of 43 publications